Last updated: March 6, 2026
What are the key facts of the case?
AstraZeneca AB filed patent infringement litigation against Apotex Inc. in the U.S. District Court for the District of Delaware. The case number is 1:18-cv-02010. The dispute centers on the approval and sale of generic versions of Symbicort (budesonide/formoterol fumarate), a respiratory medication marketed by AstraZeneca.
AstraZeneca holds patents related to the formulation and manufacturing process of Symbicort. Apotex sought FDA approval for a generic generic version, challenging AstraZeneca's patents. AstraZeneca asserted that Apotex’s product infringes on its patents and sought injunctive relief and damages.
What patents are at issue?
AstraZeneca’s patents include:
- US Patent No. 8,563,682: Encompasses methods of treatment with budesonide and formoterol.
- US Patent No. 8,529,651: Covers specific formulations of budesonide/formoterol.
The patents expire between 2025 and 2028. AstraZeneca argues Apotex’s generic infringes these patents by manufacturing a bioequivalent drug.
What are the main legal issues?
Patent validity
A critical issue is whether AstraZeneca’s patents are valid under 35 U.S.C. § 102 and § 103, considering prior art references and obviousness.
Patent infringement
Whether Apotex’s generic product infringes on AstraZeneca’s asserted patents, either literally or under the doctrine of equivalents.
Paragraph IV certification
Apotex filed an Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification, asserting that AstraZeneca’s patents are invalid or unenforceable, and seeking FDA approval for the generic.
Injunctive relief
AstraZeneca seeks a preliminary and permanent injunction to prevent sale of Apotex’s generic until patents expire.
What procedural actions occurred?
- 2018: Apotex filed ANDA with Paragraph IV certification, triggering patent infringement litigation.
- 2018-2020: Discovery phase, including patent claim construction hearings.
- 2020: Summary judgment motions on patent validity and infringement.
- 2021: Trial on patent issues resulted in mixed findings; some patents upheld, others invalidated.
- 2022: Appeals filed; court issued final rulings on injunction and damages.
What are the recent developments?
The court granted AstraZeneca preliminary injunctive relief against Apotex, blocking the sale of its generic product until the patent expiry or further court ruling. The final judgment found that, in the case of certain patents, Apotex’s product would infringe AstraZeneca’s rights, and those patents were deemed valid.
AstraZeneca was awarded damages based on Apotex’s sales of the infringing product during the infringement period. Apotex appeals the validity and infringement rulings.
Financial implications
AstraZeneca reports annual revenue of approximately $1.0 billion from Symbicort. The potential market loss from generic entry is estimated at 80%, translating into approximately $800 million annually. Court rulings favoring AstraZeneca delay generic market entry, preserving revenue.
Strategic implications
AstraZeneca’s patent portfolio remains enforceable against this particular generic. The injunction and damages help protect its market share. Apotex’s ongoing appeal and potential for patent invalidation could open a path for future generics if successful.
Key Takeaways
- The case underscores the importance of patent robustness in biologic and combination drug markets.
- Court rulings currently favor AstraZeneca, with injunctive relief preventing Apotex’s market entry.
- Patent validity remains contested, with ongoing appeals possibly affecting timelines.
- The dispute illustrates the high stakes of ANDA litigation, especially in high-revenue biotech drugs.
- AstraZeneca’s patent strategy protects significant revenue streams; litigation acts as a deterrent for generic competition.
FAQs
1. What is the significance of a Paragraph IV certification?
It signals the generic company believes AstraZeneca’s patents are invalid or unenforceable, initiating patent infringement litigation and delaying generic entry.
2. How long do AstraZeneca’s patents on Symbicort last?
The patents are set to expire between 2025 and 2028, depending on jurisdiction and patent-specific factors.
3. What is the likely impact of this case on generic drug approvals?
Successful patent defenses delay generic approval, preserving brand revenue and deterring potential entrants.
4. Can Apotex challenge the patents further?
Yes, through appeals and patent invalidity proceedings, potentially leading to patent invalidation or reinforcement.
5. How does the court determine patent infringement?
By interpreting patent claims and comparing them to the accused product, considering literal infringement and equivalents.
References
- U.S. District Court for the District of Delaware. AstraZeneca AB v. Apotex Inc., Case No. 1:18-cv-02010.
- U.S. Patent and Trademark Office. Patent numbers 8,563,682 and 8,529,651.
- Food and Drug Administration. ANDA approvals and Paragraph IV certifications.
